OMEICOS Therapeutics GmbH - Board

Board

Dr. Bernhard Kirschbaum, Chairman

Bernhard Kirschbaum, PhD studied and researched in biochemistry and physiological chemistry at the University of Konstanz (Germany), receiving his PhD in 1989. He moved on to work at the Rockefeller University (New Yortk) and the Pasteur Institute (Paris).  Subsequently, he joined the pharmaceutical industry where he covered a broad range of technological and disease areas. Before his retirement as executive Bernhard Kirschbaum was head of Global Research and Early Development at Merck Serono.  In this role he was a member of the Pharmaceutical Executive Committee. Prior to joining Merck KGaA in 2005 he was Vice President Discovery Research, Global Head of Therapeutic Domains “Thrombosis & Angiogenesis” for Sanofi-Aventis. He also worked for Aventis, Hoechst Marion Roussel in various senior positions and headed the Centre of Applied Genomics in Martinsried. Bernhard Kirschbaum is currently member of several biotech company boards.

Dr. Christian Schneider

Dr. Christian Schneider is a managing Partner of Vesalius Biocapital and has been a venture capital executive for more than 15 years. He gained extensive work and investment experience in the areas of diagnostics, medtech, and therapeutics in positions of increasing responsibility in the life science and venture capital industry.
 
At Boehringer Mannheim/Roche (Germany, 1992-1995), he developed the first fully automated test for a new prostate cancer marker, free PSA, which is marketed by Roche worldwide. Subsequently, at Centocor (Pennsylvania, USA, 1995-2000, sold to Johnson&Johnson for USD 5B in 1999), he led the development of a panel of tumor markers in a transatlantic collaboration between Centocor and Boehringer Mannheim/Roche. Later, as a business developer and external research manager in Centocor’s / Johnson&Johnson’s biological therapeutics business, he negotiated licenses and development agreements, and managed international early-stage product development projects.
 
As a managing partner of venture capital firm PolyTechnos (Germany 2001-2008), he was directly responsible for the investments in and IPOs of OncoMethylome Sciences (Euronext, 2006), Devgen (Euronext, 2005) and Jerini (Frankfurt, 2005). As a support partner, he was further responsible for the investments and exits of Addex (SWIX, 2007) and BiPar (USD 500 m trade-sale to Sanofi-Aventis, 2009). He served as an independent director on the boards of Hepa Wash and MagnaMedics. Dr. Schneider joined the pan-European life science venture capital firm Vesalius Biocapital as a Managing Partner in 2008. He was responsible for the investments and exits of Skyline (write-off) and Activaero (EUR 130m trade sale to Vectura, 2014) and currently serves on the boards of portfolio companies Ventaleon,  Omeicos, and Humedics.
 
Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).

Peter Seiler

Head of Treasury Vice President SMS GmbH

Dr. Martin Pfister

Senior Investment Manager HighTech Gründerfonds

Ute Mercker

Investment Director / Authorised Officer at IBB
 
Ute Mercker is Investment Director at the Life Sciences Team of IBB Beteiligungsgesellschaft, the regional Venture Capital funds of Berlin.
 
Since 1997 she had been responsible for IBB´s Biotech and Medtech portfolio and managing investments into companies like Jerini or Scienion. Spin-offs from Universities or research institutions like Humedics, Scopis and EternyGen have always been an important part of her investment activities. Ute enjoys discussing and developing strategic and financial options with the founders / management / Board of their portfolio companies.
 
Since 2001 Ute Mercker had been serving as Deputy Chairwoman of the Supervisory Board of Scienion AG and she was appointed as member of the Board of Omeicos GmbH in March 2015. Ute represents the funds managed by IBB Beteiligungsgesellschaft on the Board of Humedics and caprotec.
 
She holds an MBA from the Freie Universität Berlin.

Dr. Gaston Matthyssens

Dr. Gaston Matthyssens has a Ph.D. and M.Sc. from the Free University of Brussels. He received training in the laboratories of three Nobel Prize winners, Dr. Susumu Tonegawa at the Basel Institute of Immunology and Dr. Cesar Milstein and Fred Sanger at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England.
 
Following an academic career as Professor at the Free University of Brussels, Gaston joined the biotech company Plant Genetic Systems NV in 1986 as a member of the management team and laboratory director. Plant Genetics Systems was acquired by Hoechst Agrevo for USD 750m.
 
When his protein-engineering group was acquired in 1991 by Corvas International, San Diego, he became its European Vice President responsible for drug discovery and international operations.
 
In 1997 Gaston became VP Business Development for the Flanders Institute for Biotechnology (VIB), Gent, Belgium, where he identified mature intellectual property and conceptualized new businesses around it. He was responsible for setting up the businesses, recruiting management and forming venture capital syndicates for VIB's first three spin-offs: deVGen (successfully floated on Euronext in 2005), CropDesign (sold to BASF) and Ablynx (successfully floated on Euronext in 2007). In total Gaston was responsible for raising EUR 18m in seed money for these companies.
 
Before joining Vesalius Biocapital, he was a partner at Value4Growth, a consulting firm specializing in start-up companies, and worked with Mr Verdood and Mr Geldhof since 2001.

Dr. Wolf-Hagen Schunck

Max-Delbrück-Center for Molecular Medicine (MDC)
Dr. Schunck represents the group of scientific founders in the Board of Directors of OMEICOS. He is a biochemist at the Max Delbrueck Center for Molecular Medicine in Berlin-Buch and has over 30 years of research experience in the field of cytochrome P450 (CYP) enzymes.

In the late 1990s, Dr. Schunck’s laboratory started to investigate mammalian CYP enzymes involved in the formation of bioactive lipid mediators derived from omega-6 and omega-3 polyunsaturated fatty acids (PUFAs). Collaborating with cardiologists and nephrologists, he became interested in the role of CYP-eicosanoids as mediators of intrinsic mechanisms protecting against cardiac and renal injury. Searching for metabolites mediating the cardioprotective effects of omega-3 PUFAs, Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) as the most promising candidate and developed together with Dr. John R. Falck from the UTSW in Dallas robust synthetic analogues for in vivo administration.

From 2010 to 2013, Dr. Schunck supervised the MDC-granted PreGoBio-project on the development of novel eicosanoid-like antiarrhythmic drugs that provided the scientific basis for the foundation of OMEICOS.
The research of Dr. Schunck yielded 98 publications, the title of which can be retrieved from Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/?term=schunck-wh.

The current work of Dr. Schunck is focused on dissecting the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.